Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal irinotecan + oxaliplatin + 5-fluorouracil for first-line advanced pancreatic cancer
ChiCTR2400093900Phase 4Recruiting
- Sponsor
- Beijing Chaoyang Sanhuan Cancer Hospital
- Start
- Dec 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan liposome, oxaliplatin and fluorouracil in pancreatic cancer (PC), sponsored by Beijing Chaoyang Sanhuan Cancer Hospital. Primary endpoint: Objective response rate. Started Dec 2024; status: recruiting.
02
Drugs
irinotecan liposomeoxaliplatinfluorouracil
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2400093900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093900.